3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma, Ewing
4
Ovarian Neoplasms
4
Uterine Neoplasms
2
Uterine Cervical Neoplasms
2
Sarcoma
2
Neoplasms
2
Melanoma
2
Carcinoma, Non-Small-Cell Lung
2
Rare Diseases
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasms, Connective and Soft Tissue
1
Neoplasms, Connective Tissue
1
Neoplasms, Bone Tissue
1
Neoplasms by Histologic Type
1
Lung Neoplasms
1
Liver Neoplasms
1
Fallopian Tube Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Interventions
robatumumab
1
pegfilgrastim
1
omburtamab I-131
1
lenvatinib
1
exatecan
1
cixutumumab
1
amino-acid, glucose, and electrolyte solution
1
Temozolomide
1
Irinotecan
1
Fentanyl
1
FANG vaccine
1
Everolimus
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neuroectodermal Tumors, Primitive, Peripheral
×
FANG vaccine
×
Clear all
NCT03495921
2023-04-26
VITA
Gradalis, Inc.
Phase 3
Terminated
32 enrolled
13 charts